INDIANAPOLIS, May 18, 2011 /PRNewswire/ -- Eli Lilly and Company (NYSE: LLY) today announced that David M. Kendall, M.D., currently chief scientific and medical officer of the American Diabetes Association, has been named distinguished medical fellow for Lilly. He will transition from his current role in late-July.
In his new role, Kendall will serve as a senior medical advisor for Lilly Diabetes in advocacy and clinical science communities and as a representative to the professional medical community. In addition, he will help provide scientific direction for Lilly in diabetes discovery and clinical development. Other key responsibilities will include the support of Lilly's medical education efforts and diabetes healthcare evaluation programs.
"David brings a critical external view, including the insights he gained while at the American Diabetes Association," said Enrique Conterno, president of Lilly Diabetes. "We are working hard to gain leadership in diabetes care, and that leadership must start with an understanding of the needs of patients and health care providers."
Kendall will report to Robert Heine, M.D., vice president medical affairs, Lilly Diabetes.
"With his background as a clinician, researcher and diabetes advocate, David is the ideal candidate for this position," said Heine. "His focus, passion and understanding of diabetes care will enable us to create ever better solutions for people living with diabetes."
About David Kendall
Kendall joins Lilly Diabetes from the American Diabetes Association, where he serves as scientific and medical officer and has been responsible for the oversight of the Association's research programs, medical affairs, medical education, international affairs, medical information and community programs since 2009.
Kendall also is an associate professor of medicine at the University of Mi
|SOURCE Eli Lilly and Company|
Copyright©2010 PR Newswire.
All rights reserved